Regarding survival implications of PCP alterations, although breast cancer patients in TCGA cohort with no amplifications in VANGL2 or NOS1AP had a somewhat better OS than patients with amplifications in either or both genes, this difference does not reach statistical significance (Log Rank p = 0.19; Figure 7). This evidence concerns the gene VANGL2 and breast carcinoma.